CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis by G. Markel et al.
Oncotarget17885www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 14
CEACAM1 and MICA as novel serum biomarkers in patients with 
acute and recurrent pericarditis
Gal Markel1,2,3, Massimo Imazio4, Nira Koren-Morag5, Gilli Galore-Haskel1, Jacob 
Schachter1, Michal Besser1,3, Davide Cumetti6, Silvia Maestroni6, Arie Altman7, 
Yehuda Shoenfeld8, Antonio Brucato6, Yehuda Adler2,9,10
1 Ella Lemelbaum Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
2 Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Israel
3 Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
4 Cardiology Department, Maria Vittoria Hospital, Torino, Italy
5 Department of Epidemiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
6Internal Medicine, Ospedali Riuniti, Bergamo, Italy
7Internal Medicine B, Sheba Medical Center, Tel Hashomer, Israel
8 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
9 Cardiac Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, Israel
10 Department of Internal Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Correspondence to:  Yehuda Adler, e-mail: adlery@post.tau.ac.il
 Gal Markel, e-mail: markel@post.tau.ac.il
Keywords: pericarditis, serum, biomarkers, MICA, MICB
Received: October 03, 2015 Accepted: January 23, 2016 Published: February 20, 2016
ABSTRACT
Background: The immune response plays a significant role in pericarditis, but the 
mechanisms of disease are poorly defined. Further, efficient monitoring and predictive 
clinical tools are unavailable. Carcinoembryonic antigen cell adhesion molecule 1 
(CEACAM1) is an immune-inhibitory protein, while MHC class I chain related protein 
A (MICA) and B (MICB) have an immune-stimulating function.
Methods and results: Serum CEACAM1, MICA and MICB concentrations were 
measured by ELISA in ~50 subjects of each group: acute pericarditis (AP), recurrent 
pericarditis (RP) and lupus (SLE) patients, metastatic melanoma patients as well as 
healthy donors. Serum CEACAM1 was dramatically elevated in AP and RP patients, 
but not in SLE patients, and displayed a highly accurate profile in ROC curve analyses. 
MICA and MICB were elevated in some pericarditis patients. All markers were 
enhanced in metastatic melanoma patients irrespective of neoplastic pericardial 
involvement. Etiology-guided analysis of RP patients showed that very low MICA 
levels were associated with idiopathic RP, while high MICA was associated with 
autoimmune and post-operative RP. Importantly, MICA was significantly associated 
with recurrences, independently of other potentially confounding parameters such 
as age, time of follow up or treatment modality. 
Conclusions: Here we report for the first time on CEACAM1 as a potentially novel 
biomarker for pericarditis, as well as on MICA as an innovative prognostic marker in 
these patients. Determination of the roles of these immune factors, as well as their 
diagnostic and prognostic values should be determined in future prospective studies.
INTRODUCTION
Acute pericarditis (AP) is an inflammatory disease of 
the pericardium, diagnosed in one in every 1000 hospital 
admissions in the United States [1]. Several etiologies may 
account for AP, including viral, bacterial, autoimmune, 
post-pericardiotomy, postmyocardial infarction, cardiac 
trauma, metabolic and neoplasm [2]. Employing invasive 
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procedures such as pericardioscopy or pericardial biopsy 
can diagnose the etiology in the vast majority of the cases 
[2]. Unfortunately, these are not performed in most medical 
centers on a routine basis. Thus, the etiology in developed 
countries with a low prevalence of tuberculosis remains 
unknown (idiopathic) in 85% of the cases. Treatment 
usually consists of empirical anti-inflammatory therapies, 
such as non-steroidal anti-inflammatory drug (NSAID), 
corticosteroids, colchicine and treatment of the underlying 
cause, when possible [1]. Recurrent pericarditis (RP) is 
generally manifested by recurrence of AP symptoms after 
resolution and elimination of the inciting agent [3–5]. RP 
develops in 30% of AP patients not treated with colchicine 
[3–7], usually within 18 to 20 months after the initial AP 
episode, but may occur after longer periods [7, 8]. The 
disease usually has a relapsing-remitting pattern [3–5], but 
may be more chronic in some cases [9].
Based on serological findings and frequent 
responsiveness to immunosuppressive therapy, the immune 
system seems to play a role in RP. European investigators 
have recently demonstrated a higher prevalence of 
infectious etiology (infection or re-infection) by employing 
pericardioscopy, epicardial biopsy and polymerase chain 
reaction [9, 10]. Thus, autoreactive pericarditis can be 
determined only if other etiologies have been excluded and 
pericardial fluid analysis reveals several immunological 
features, including increased number of mononuclear cells, 
anti-sarcolemmal antibodies and inflammatory cytokines 
(interleukins-6 and 8 and interferon-gamma) [9, 10]. 
Clinical features have a limited yield in predicting the 
development of RP, but lack of response to NSAID treatment 
increases the risk for RP and pericardial constriction [11]. 
Similarly, inappropriate corticosteroid therapy in AP 
promotes development of RP, possibly due to enhanced 
viral replication [6, 11–13]. Up to date, the biological 
mechanisms for relapses are still elusive, and there are no 
reliable biomarkers with the capability to predict or monitor 
development of relapses.
MICA and MICB are encoded in the MHC cluster 
and share certain homology with HLA class I genes 
(28–35%) [14]. Normally, MICA and MICB are expressed 
by intestinal epithelium [15]. However, induction of MICA 
and MICB expression by a broad spectrum of cells occurs 
in response to cellular stress, such as transformation, 
infection and hypoxia [15]. These proteins are ligands 
for the powerful lymphocyte killer receptor NKG2D 
[16]. Carcinoembryonic Antigen Cell Adhesion Molecule 
(CEACAM) -1 is a multifunctional glycoprotein that 
directly inhibits various effector functions of NK and 
T cells, such as IFNγ release and killing activities, via 
homophilic intercellular interactions [17, 18]. This 
mechanism is exploited by tumor cells [19, 20], viruses [21] 
and fetal trophoblasts [21]. 
Here we study these three proteins in the serum of 
49 AP patients, 48 RP patients and 47 demographically 
matched healthy donors, as well as in 50 patients with a 
known autoimmune disease (SLE) and in 44 metastatic 
melanoma patients. The potential implications on the 
immuno-pathogenesis of pericarditis, as well as the potential 
implementations as innovative clinical tools are discussed.
RESULTS
Comparative analysis of inflammatory cytokines 
Serum samples were obtained from 49 patients 
afflicted with acute pericarditis (AP), 48 patients with 
recurrent episodes of acute pericarditis (RP) and 47 
demographically matched controls. These groups were 
comprised of 29 males and 20 females, 29 males and 19 
females, and 27 males and 20 females, respectively (Table 1). 
There were no significant differences between males 
and females in all parameters among all experimental 
groups, including the median follow up time and the 
number of recurrences in the RP group. The patients 
were not selected for a certain treatment or inflammatory 
index (data not shown). SLE and melanoma served as 
reference diseases. SLE represents a chronic state of 
autoimmune inflammation, which commonly affects 
serosal surfaces such as the pericardium. There is no data 
on soluble CEACAM1, MICA or MICB in SLE. Pericardial 
involvement by cancer is represented here by melanoma, 
as 44 metastatic melanoma patients were included, 18 with 
neoplastic pericardial effusion and 26 without neoplastic 
pericardial effusion. Serum CEACAM1, MICA and MICB 
were previously reported as poor prognostic markers 
in melanoma [22–25], but the relevance of pericardial 
involvement has never been evaluated.
We studied the expression of inflammatory cytokines 
including IL-6, CXCL8 and IFNγ. In line with previous 
reports [26], the serum levels of IL-6 and CXCL8 were 
not significantly elevated among AP and RP patients, as 
opposed to higher levels observed in metastatic melanoma 
patients, similar to previously reports [27, 28] (Figure 1). 
Serum levels of IFNγ were somewhat higher in all of 
the different patient groups, but statistical significance 
was demonstrated only among the SLE and RP patients 
(Figure 1). There were no significant differences between 
melanoma patients with or without pericardial effusion 
(Figure 1). As expected, the highest CRP level was 
observed among the AP patients, but also significantly 
higher levels than in healthy donors were observed in 
the RP patients (Figure 1). There were no differences in 
inflammatory cytokine levels among males and females 
(data not shown). 
As previous reports failed to associate the 
inflammatory cytokines, which probably emanate from 
innate immunity components, with certain etiologies or 
with prognostic parameters, we decided to focus on other 
novel serum markers, CEACAM1, MICA and MICB. 
These proteins probably emanate from the injured tissue 
and have immune regulatory functions, as detailed in the 
introduction, and therefore might provide new insights 
on pericardial diseases. 
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Table 1: Basic clinical data 
Parameter Males Females P value All
Healthy
N 27 20 − 47
Age (years) 48 50.4 0.73 49
AP
N 29 20 − 49
Age (years) 46.1 48.2 0.65 47
RP
N 29 19 − 48
Age (years) 46.2 48.2 0.88 47
Follow up (years) 5.5 4.8 0.42 5.2
Recurrences (N) 5.5 3 0.13 4.5
Table describes demographic data of healthy donors, AP and RP patients, selected clinical parameters and concentration of 
each of the biomarkers. 
Figure 1: Distribution analysis of inflammatory biomarkers. Distribution analysis of each of the indicated biomarkers according 
to serum concentrations (y-axis) in each group of subjects: healthy donors (Healthy), acute pericarditis patients (AP), recurrent pericarditis 
patients (RP), systemic lupus erythematosis patients (SLE), metastatic melanoma (Mel) with or without pericardial involvement (+/− eff). 
Boxes and Whiskers present all data, horizontal line reflects the median value. Statistical significance was tested with Kruskal-Wallis test: 
***denotes P < 0.0001, **denotes P < 0.01 and *denotes P < 0.05.
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Characteristics of CEACAM1, MICA and MICB 
as serum biomarkers in healthy donors 
Distribution analysis of serum CEACAM1, MICA and 
MICB levels was carried out in healthy donors. CEACAM1 
displayed normal distribution pattern with narrow range and 
a peak at 60 ng/ml. MICA displayed a relatively narrow 
range, varying between below threshold of detection 
to several dozens of pg/ml. MICB demonstrated high 
variability with an abnormal distribution pattern, ranging 
from below threshold of detection, through several dozens 
and hundreds, to several thousands of pg/ml (Figure 2A). 
A strong correlation was observed between MICA and age 
(r = 0.76, p < 0.0001) and an intermediate inverse correlation 
was observed between CEACAM1 and age (r = −0.46, 
p = 0.001). These were further confirmed by a linear 
regression analysis (p < 0.0001 and p = 0.0002, respectively). 
However, these associations occur over a narrow range of 
values, thus the biological significance of these findings is 
unclear. MICB did not correlate with age (Figure 2B). There 
were no significant differences in CEACAM1, MICA and 
MICB between males and females (data not shown). 
Patients with pericarditis show significantly 
different pattern of serum CEACAM1, MICA 
and MICB
Serum CEACAM1 levels were markedly elevated 
in AP patients (2.9-fold, p < 0.0001) and in RP patients 
(2.1-fold in average, p < 0.0001), as compared to the healthy 
donors. Noteworthy, CEACAM1 was significantly elevated 
in AP patients as compared to RP patients (p < 0.001) 
(Figure 3A). CEACAM1 serum levels in SLE patients 
(n = 50) and healthy donors were similar (Figure 3A). Higher 
serum MICA levels were observed in AP patients (2.7-fold, 
p = 0.05) and SLE patients (10-fold, p < 0.01), as compared 
to healthy donors and RP patients (Figure 3A). Serum MICB 
levels were significantly higher in the AP patients (9.6-fold in 
average, p < 0.05) and in SLE patients (7.6-fold in average, 
p < 0.05), as compared to healthy donors and RP patients. In 
line with previous reports [22, 29], all three markers were 
detected in significantly higher levels among metastatic 
melanoma patients. Importantly, there were no differences 
in these serum markers among melanoma patients with 
or without neoplastic pericardial effusion (Figure 3A). 
Noteworthy, the correlations of CEACAM1 and MICA with 
age observed in healthy donors (Figure 1B) were not evident 
in the AP and RP patient populations (Table 2A). 
ROC curves showed an extremely high accuracy 
of serum CEACAM1 in pericarditis patients, with 
AUC values of 0.995 and 0.943 for AP and RP patients, 
respectively (Figure 3B–3C). In SLE patients, however, 
the AUC for serum CEACAM1 ROC curve was 0.74 
(Figure 3D). ROC curves of MICA and MICB show low 
accuracy for AP, RP and SLE patients (Figure 3B–3D). 
ROC curves were not calculated for the melanoma 
patients, as metastatic malignancy is an entirely different 
clinical setup than pericarditis, with known association 
with these three tumor markers. 
None of the markers correlated with each other 
in healthy donors (Table 2B), or with any of the 
inflammatory cytokines tested, IFNγ or IL-6 (data not 
shown). In AP patients, a strong correlation between 
MICA and MICB was observed (r = 0.602, p < 0.0001), 
Figure 2: Distribution analysis of biomarkers in healthy donors. (A) Distribution analysis of each of the indicated biomarkers 
according to serum concentrations (X-axis). Y-axis denotes the number of patients (frequency); (B) Correlation of each biomarker with age 
among the healthy donors. Correlation was tested with Spearman’s test, the R and P values are indicated in each plot. 
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while CEACAM1 did not correlate with MICA or MICB 
(Table 2B). In RP patients, the correlation between MICA 
and MICB was weaker but still statistically significant 
(r = 0.38, P < 0.001). Interestingly, CEACAM1 was 
inversely correlated with both MICA (r = −0.514, 
p < 0.0001) and MICB (r = −0.37, p < 0.05) (Table 2B). 
Noteworthy, the absolute concentration levels of these 
markers, except for CEACAM1, were not significantly 
different between the AP or RP patient populations and the 
healthy donors (Figure 3), only their respective associations 
with each other among the patients were. These correlations 
could imply on common regulation mechanisms that might 
be linked to the underlying pathology, but this is still 
mostly unclear.
Expectedly, a direct correlation (r = 0.478, p < 0.01) 
was observed between recurrences and time of follow-
up for all patients (Table 2C). An inverse correlation 
(r = −0.326, p < 0.05) was observed between recurrences 
and age (Table 2C), indicating on a tendency to develop 
RP at younger age. Finally, and most importantly, a solid 
correlation (r = 0.306, p < 0.05) between MICA and 
recurrences was observed (Table 2C). No similar correlation 
could be observed with MICB or CEACAM1 (Table 2C). 
None of the inflammatory markers presented in Figure 1 
demonstrated a similar correlation (data not shown).
Linkage between serum MICA and etiology of 
recurrent pericarditis
Our cohort of RP patients included 33 “idiopathic” 
patients, 7 patients with autoimmune pericarditis, 6 “post 
pericardiotomy” and 2 “post myocardial infarction” (Table 3). 
Remarkably low serum concentrations of MICA were 
observed in idiopathic RP patients, as compared to other 
etiologies of RP (Table 3, P value = 0.009). CEACAM1 
levels in idiopathic RP patients were the highest, but this 
was not of statistical significance (Table 3, P value = 0.188). 
Although some differences were observed in serum 
MICB among different etiological groups, these were not 
statistically significant (Table 3). 
The percentage of patients exhibiting biomarker 
values in the highest tertile was calculated. Remarkably, 
Figure 3: Comparison of biomarker levels between healthy donors and patients. (A) Serum levels of CEACAM1, MICA 
and MICB among four subject populations: healthy donors (Healthy), acute pericarditis patients (AP), recurrent pericarditis patients (RP), 
systemic lupus erythematosis patients (SLE) and metastatic melanoma (MM) with or without pericardial involvement (+/− eff). Each dot 
represents a patient. Statistical significance was tested with Kruskal-Wallis test: ***denotes P < 0.0001, **denotes P < 0.01 and *denotes 
P < 0.05; (B–D) ROC curves of each biomarker (indicate in the top of the Figure) for each group of patients (indicated in the left). Area 
Under the Curve (AUC) is indicated in each plot. 
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only 15% of the idiopathic RP patients exhibited high 
MICA levels, as compared to a robust 83% of post 
pericardiotomy RP patients and 57% of autoimmune RP 
(Figure 4). These results are in accordance to the statistical 
link demonstrated above (Table 4). Approximately a third 
of the idiopathic and autoimmune RP patients, and 50% 
of the post pericardiotomy and post myocardial infarction 
RP patients exhibited high values of MICB (Figure 4). 
Significantly, none of the post pericardiotomy RP patients 
exhibited high CEACAM1 values, as compared to 39% 
and 43% of the idiopathic and autoimmune patients, 
respectively (Figure 4). These results are in accordance 
with the statistical trend demonstrated above (Table 3). 
None of the inflammatory markers presented in Figure 1 
had any correlation with etiology (data not shown).
These results imply that RP etiology is associated 
with differential regulation of stress response proteins. 
Furthermore, this is the first time that an easily measurable 
Table 2: Correlations between serum biomarkers and clinical parameters
A Age-MICA Age-MICB Age-CCM1
Healthy 0.760(***) −0.151 −0.465(**)
AP −0.153 −0.124 −0.108
RP −0.059 −0.301 0.203
B MICA-MICB MICA-CCM1 MICB-CCM1
Healthy −0.005 −0.256 0.107
AP 0.602(***) 0.102 0.104
RP 0.380(**) −0.514(***) −0.370(*)
C (RP) Recurrences Age Time
Recurrences 1 −0.326(*) 0.478(**)
Age −0.326(*) 1 0.091
Time 0.478(**) 0.091 1
MICA 0.306(*) −0.059 0.1
MICB 0.029 −0.301 −0.032
CEACAM1 −0.167 0.203 0.012
Each of the three biomarkers was correlated with age (A) or with the other biomarkers (B) in healthy, AP and RP patients. 
In addition, each biomarker was correlated with recurrences, age and duration of follow up (time) in RP patients only (C). 
Correlation was calculated by Spearman’s test. The values in the table represent Spearman’s R. *denotes p < 0.05, **denotes 
p < 0.01 and ***denotes p < 0.001.
Table 3: Correlations between serum biomarkers and RP etiology
Etiology N
Median MICA Median MICB
Median
CEACAM1
(pg/ml) (pg/ml) (ng/ml)
Idiopathic 33 3 0 171
Autoimmune 7 65 0 151
Post pericardiotomy 6 118 317 130
Post myocardial infarction 2 179 1223 133
P value 0.009 0.466 0.188
Chi square
Patients were categorized into four main etiological groups, as indicated in the table. The median values of the biomarkers for 
each etiological group are presented. Statistical significance was tested with Kruskal-Wallis test.
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serum marker (MICA) can potentially discriminate 
between idiopathic RP and other causes of RP.
Serum MICA correlates with recurrences in RP 
patients irrespectively of treatment regimen
The potential effect of various treatment regimens 
on the tested serum biomarkers values was evaluated in 
the RP patients. Treatment categories included colchicine 
only, colchicine and corticosteroids, colchicine and 
NSAIDs, and no colchicine or all (Table 4). At the time 
of sampling, 26 patients did not receive any treatment, 8 
were on colchicine only, 5 on all three modalities, 4 on 
steroids + colchicine, 2 on NASAIDs + colchicine, 2 on 
steroids only and 1 on NSAIDs only. An improved clinical 
outcome of patients treated with colchicine and NSAIDs, 
or with colchicine and steroids, was observed, as these 
patients experienced significantly less recurrences (Table 4). 
Importantly, a clear trend towards very low MICA values 
was observed in these patients (Table 4, P value = 0.10). 
This strongly implies that serum MICA concentration 
reflects number of recurrences and is independent of 
the treatment regimen (Table 4). In addition, a similar 
trend for higher CEACAM1 values was observed in 
the same treatment groups (Table 4, P value = 0.12). 
This finding supports the inverse correlation between 
MICA and CEACAM1 depicted above (Table 2). Despite 
the apparent differences in MICB values, these were not 
statistically significant (Table 4, P value = 0.63). There were 
no correlations between any of the serum biomarkers and 
severe adverse effects of colchicine mandating treatment 
discontinuation (data not shown).
DISCUSSION
Pericarditis (acute and chronic) is an inflammatory 
disorder with several identified etiologies [1, 3, 5]. The 
specific etiology usually remains unknown as diagnostic 
invasive procedures are not commonly performed. 
A substantial portion of these cases is most probably 
caused by viral infections [9, 10]. Currently, the immuno-
pathogenesis of pericarditis is still mostly unknown, and 
there are no accessible predictive biomarkers. The lack 
of reliable clinical tools for diagnosis, monitoring and 
prediction of RP is a withstanding clinical deficit. Few 
studies on the diagnostic potential of cardiac Troponin I 
in viral acute pericarditis [30], pericardial fluid adenosine 
deaminase for tuberculous RP [31, 32] and classical tumor 
markers like CEA for neoplastic RP [33] were published. 
Here we investigate the involvement of serum CEACAM1, 
MICA and MICB, proteins that can be induced in damaged 
or inflamed tissues, in pericarditis patients.
Cell surface expression of CEACAM1 is induced 
by viral infection [21] and inflammatory cytokines such 
as IFNγ [20]. MICA and MICB are induced by similar 
conditions [15]. Specifically in the heart, it was reported that 
CEACAM1 expression is induced upon hypoxic injury [34] 
and that tissue-expressed MICA and MICB were implicated 
in allograft rejection [35]. As some of these conditions may 
play a role in pericarditis, upregulation of CEACAM1, 
MICA or MICB could be anticipated in situ. It has been 
demonstrated in several reports that MICA or MICB 
proteins are shed by tumor cells in many types of cancers 
with potential prognostic value [36–38]. Remarkably, it was 
recently reported that in multiple sclerosis (MS) patients, 
serum MICB levels are increased and are associated with 
relapse [39]. In addition, it has recently been shown that the 
presence of soluble CEACAM1 in the serum reflects tumor 
burden in pancreatic adenocarcinoma patients [40] and may 
have prognostic importance in melanoma patients [22]. 
Collectively, these prompted the investigation of serum 
CEACAM1, MICA and MICB in pericarditis patients.
We show high serum CEACAM1 levels and 
efficient ROC curves in AP and RP patients (Figure 3). 
The underlying biochemical mechanism is still elusive, as 
it could be due to unique splicing in the injured pericardial 
cells, like we’ve previously suggested for melanoma 
cells [22], or due to other mechanisms such as proteolytic 
Figure 4: Distribution of RP patients exhibiting high values of biomarkers according to etiological groups. Figure shows 
the percentage of RP patients exhibiting biomarker values in the highest tertile. Patients are categorized in each of the indicated etiological 
groups.
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cleavage. The high serum CEACAM1 levels observed in 
metastatic melanoma patients is irrespective of neoplastic 
pericardial involvement (Figure 3), implying that different 
patho-physiological mechanisms account for the enhanced 
serum CEACAM1 in pericarditis patients. Following this 
line, serum CEACAM1 concentrations were not elevated in 
patients with an autoimmune disease like SLE (Figure 3), 
suggesting on disease specific mechanisms among 
inflammatory conditions. Further mechanistic studies are 
mandated, including a biochemical analysis of the serum 
CEACAM1 in the pericarditis patients. Clinically, the 
evidence point on a potential diagnostic relevance of serum 
CEACAM1 in pericarditis patients, which should be further 
explored in larger prospective clinical trials.
Serum MICA and MICB levels were elevated in 
some of the pericarditis patients, but without reaching 
statistical significance or efficient ROC curves (Figure 3). 
MICA and MICB were strongly elevated in SLE patients 
and in patients with metastatic melanoma, irrespective of 
neoplastic pericardial involvement (Figure 3). This argues 
against a significant diagnostic role for MICA and MICB in 
pericarditis. Nevertheless, among RP patients, a significant 
positive correlation between serum MICA concentrations 
with recurrences was observed, independently of other 
potentially confounding parameters linked to recurrences, 
such as age and time of follow up (Table 2), or the 
therapeutic regimen (Table 4). In normal donors, MICA 
positively correlates with age (Figure 2), a correlation that 
is lost in pericarditis patients (Table 2). This indicates on a 
prognostic value of MICA. An extended group of subjects 
is required to conduct a prospective multivariate analysis 
to evaluate the full predictive prognostic potential of MICA 
in RP patients.
The elevation in MIC proteins could be explained 
either by systemic spillage from the site of inflammation 
or from other reactive remote sites, created by protein 
cleavage by metalloproteinases or secretion of soluble 
MIC forms [41]. Elevated serum MICA and MICB were 
reported in cancer and autoimmune conditions [36−38, 
42, 43]. It was also reported that MICB is upregulated 
within active MS lesions, which may be the source 
for elevated serum MICB in active MS patients [39]. 
Our findings imply on a potential role for MICA in 
pericarditis, as it is associated with recurrence. Increased 
levels of serum MICA cause systemic downregulation 
of NKG2D expression [42, 44]. Theoretically, this may 
result in increased susceptibility to viral infection or 
re-activation, directly leading to recurrences. Indeed, 
it has been demonstrated more than 2 decades ago 
that NK cell cytotoxic activity in vitro is decreased in 
perimyocarditis patients [45]. Mechanistic studies on 
pericardial specimens, epicardial fluids and peripheral 
blood lymphocytes are thus mandated. 
MATERIALS AND METHODS
Patients
We enrolled all consecutive patients with acute and 
recurrent pericarditis seen at Niguarda Hospital, Milan, since 
1998 to 2004, who gave written informed consent and whose 
sera was available for analysis, stored at –20°C. Inclusion 
criteria were: definite diagnosis of acute or recurrent 
pericarditis (idiopathic, viral, and autoimmune etiologies 
including post-pericardiotomy syndromes, and connective 
tissue diseases), age ≥ 18 years. Exclusion criteria were: 
bacterial (tuberculous, purulent), and neoplastic etiologies. 
The clinical diagnosis of recurrence was based at least on 
recurrent chest pain and one or more of the following signs: 
fever, pericardial friction rub, electrocardiographic changes, 
echocardiographic evidence of new or worsening pericardial 
effusion. Elevation of C-reactive protein or increased 
erythrocyte sedimentation rate was required in all cases to 
confirm the diagnosis of recurrence. Age and sex-matched 
controls were included from healthy blood donors recruited 
in the same time interval. Serum samples of diagnosed SLE 
patients, who gave their informed consent, were collected 
in Sheba Medical Center between the years 2004–2009. 
Serum from metastatic melanoma patients, who gave their 
written informed consent, was collected between the years 
Table 4: Association between treatment and serum biomarkers
N MICA(pg/ml)
MICB
(pg/ml)
CEACAM1
(ng/ml)
Recurrences
(median)
All treatments 5 110 0 124 7.0
Colchicine + NSAID 13 3 138 158 3.0
Colchicine + steroids 20 3 0 188 3.5
No Colchicine 4 53 140 156 8.0
Only Colchicine 6 19 92 151 4.5
P value 0.10 0.63 0.12 0.03
Patients were categorized according to treatment combinations as indicated in the table. Biomarker and recurrence values 
presented are the median value of the group. Statistical significance was tested with Kruskal-Wallis test.
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2006–2014 (IRB approval 847111). Pericardial effusion was 
primarily documented by disease evaluation CT scans.
ELISA
Soluble MICA, MICB, IL-6, CXCL8 (IL-8), and 
IFNγ were quantified in serum samples by using commercial 
sandwich ELISA kits according to manufacturer’s 
instructions (R & D Systems). Customized CEACAM1 
sandwich ELISA was performed as previously described 
[22], based on an in-house developed mAb to CEACAM1 
[19]. Each sample was tested twice in triplicates. CRP was 
determined by the hospital’s accredited clinical automated 
routine lab.
Statistical analysis
All statistical analyses were performed with SPSS 
ver. 14.0 or with Prism GraphPad ver. 5.
The distributions of the biomarkers were examined 
using the Kolmogorov-Smirnov non-parametric test. 
Kruskal-Wallis test was used to test: a) the differences 
in various biomarkers between healthy donors, AP, RP, 
SLE and melanoma patients; b) the differences in various 
biomarkers among different etiologies and treatments in 
the RP group. The association between biomarker values 
and etiology was further analyzed by dichotomous cutoff: 
biomarker values below and above the highest tertile. ROC 
curves were established for each biomarker and the AUC 
values were calculated. Spearman’s test was used to examine 
the correlations in a multi-parameter matrix comprised of 
CEACAM1, MICA, MICB, age, recurrences and time of 
follow up. The significance levels were set at 0.05. 
FUNDING
Aronson Fund (GM).
CONFLICTS OF INTEREST
There are no financial conflicts of interests to 
disclose.
REFERENCES
 1. Spodick DH. Pericardial diseases. (Philadelpiha: WB 
Saunders & Co). 2001.
 2. Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmuller R, 
Adler Y, Tomkowski WZ, Thiene G, Yacoub MH. Guidelines 
on the diagnosis and management of pericardial diseases 
executive summary; The Task force on the diagnosis and 
management of pericardial diseases of the European society 
of cardiology. Eur Heart J. 2004; 25:587–610.
 3. Robinson J, Brigden W. Recurrent pericarditis. Br Med J. 
1968; 2:272–275.
 4. Shabetai R. Recurrent pericarditis: recent advances and 
remaining questions. Circulation. 2005; 112:1921–1923.
 5. Fowler NO. Recurrent pericarditis. Cardiol Clin. 1990; 
8:621–626.
 6. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, 
Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, 
Belli R, Trinchero R. Colchicine in addition to conventional 
therapy for acute pericarditis: results of the COlchicine 
for acute PEricarditis (COPE) trial. Circulation. 2005; 
112:2012–2016.
 7. Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, 
Gaschino G, Demarie D, Ghisio A, Trinchero R. Day-hospital 
treatment of acute pericarditis: a management program for 
outpatient therapy. J Am Coll Cardiol. 2004; 43:1042–1046.
 8. Imazio M, Demichelis B, Parrini I, Cecchi E, Demarie D, 
Ghisio A, Belli R, Bobbio M, Trinchero R. Management, 
risk factors, and outcomes in recurrent pericarditis. Am J 
Cardiol. 2005; 96:736–739.
 9. Maisch B, Ristic AD, Pankuweit S. Intrapericardial treatment 
of autoreactive pericardial effusion with triamcinolone; the 
way to avoid side effects of systemic corticosteroid therapy. 
Eur Heart J. 2002; 23:1503–1508.
10. Maisch B. Recurrent pericarditis: mysterious or not so 
mysterious? Eur Heart J. 2005; 26:631–633.
11. Imazio M, Demichelis B, Parrini I, Cecchi E, Pomari F, 
Demarie D, Gaschino G, Ghisio A, Belli R, Trinchero R. 
Recurrent pain without objective evidence of disease in 
patients with previous idiopathic or viral acute pericarditis. 
Am J Cardiol. 2004; 94:973–975.
12. Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, 
Moratti M, Ghisio A, Belli R, Trinchero R. Colchicine as first-
choice therapy for recurrent pericarditis: results of the CORE 
(COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 
2005; 165:1987–1991.
13. Lange RA, Hillis LD. Clinical practice. Acute pericarditis. 
N Engl J Med. 2004; 351:2195–2202.
14. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second 
lineage of mammalian major histocompatibility complex class 
I genes. Proc Natl Acad Sci U S A. 1994; 91:6259–6263.
15. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. 
Cell stress-regulated human major histocompatibility complex 
class I gene expressed in gastrointestinal epithelium. Proc 
Natl Acad Sci U S A. 1996; 93:12445–12450.
16. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, 
Spies T. Activation of NK cells and T cells by NKG2D, a 
receptor for stress-inducible MICA. Science. 1999; 285: 
727–729.
17. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, 
Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, 
Mandelboim O. CD66a interactions between human 
melanoma and NK cells: a novel class I MHC-independent 
inhibitory mechanism of cytotoxicity. J Immunol. 2002; 
168:2803–2810.
Oncotarget17894www.impactjournals.com/oncotarget
18. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, 
Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, 
Mandelboim O, Orenstein A, Schachter J. Inhibition of 
human tumor-infiltrating lymphocyte effector functions by 
the homophilic carcinoembryonic cell adhesion molecule 1 
interactions. J Immunol. 2006; 177:6062–6071.
19. Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, 
Sapoznik-Danon S, Barshack I, Avivi C, Berkun Y, 
Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel 
immunotherapy for malignant melanoma with a monoclonal 
antibody that blocks CEACAM1 homophilic interactions. 
Mol Cancer Ther. 2012.
20. Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, 
Orenstein A, Berger R, Schachter J. Dynamic expression of 
protective CEACAM1 on melanoma cells during specific 
immune attack. Immunology. 2009; 126:186–200.
21. Markel G, Wolf D, Hanna J, Gazit R, Goldman-Wohl D, Lavy Y, 
Yagel S, Mandelboim O. Pivotal role of CEACAM1 protein 
in the inhibition of activated decidual lymphocyte functions. 
J Clin Invest. 2002; 110:943–953.
22. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-
Morag N, Besser MJ, Bar J, Shapira R, Kubi A, Nardini G, 
Tessone A, Treves AJ, Winkler E, et al. Systemic dysregulation 
of CEACAM1 in melanoma patients. Cancer Immunol 
Immunother. 2010; 59:215–230.
23. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, Jacob S, 
Gal M, Michal L. Serum CEACAM1 Correlates with Disease 
Progression and Survival in Malignant Melanoma Patients. 
Clin Dev Immunol. 2012; 2012:290536.
24. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, 
Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, 
Schadendorf D, Ugurel S. Differential clinical significance 
of individual NKG2D ligands in melanoma: soluble ULBP2 
as an indicator of poor prognosis superior to S100B. Clin 
Cancer Res. 2009; 15:5208–5215.
25. Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H. Serum 
soluble MICB (sMICB) correlates with disease progression 
and survival in melanoma patients. Tumour Biol. 2013; 
34:565–569.
26. Pankuweit S, Wadlich A, Meyer E, Portig I, Hufnagel G, 
Maisch B. Cytokine activation in pericardial fluids in 
different forms of pericarditis. Herz. 2000; 25:748–754.
27. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum 
concentration of angiogenic factors in malignant melanoma 
patients correlates with tumor progression and survival. 
Journal of clinical oncology. 2001; 19:577–583.
28. Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J, 
Schmidt H. Serum interleukin-6 as a prognostic biomarker 
in patients with metastatic melanoma. Melanoma Res. 
2012; 22:287–293.
29. Wu BJ, Li WP, Qian C, Ding W, Zhou ZW, Jiang H. Serum 
soluble MICB (sMICB) correlates with disease progression 
and survival in melanoma patients. Tumour Biol. 2013; 
34:565–569.
30. Imazio M, Demichelis B, Cecchi E, Belli R, Ghisio A, 
Bobbio M, Trinchero R. Cardiac troponin I in acute 
pericarditis. J Am Coll Cardiol. 2003; 42:2144–2148.
31. Burgess LJ, Reuter H, Carstens ME, Taljaard JJ, Doubell AF. 
The use of adenosine deaminase and interferon-gamma as 
diagnostic tools for tuberculous pericarditis. Chest. 2002; 
122:900–905.
32. Burgess LJ, Reuter H, Carstens ME, Taljaard JJ, Doubell AF. 
Cytokine production in patients with tuberculous pericarditis. 
Int J Tuberc Lung Dis. 2002; 6:439–446.
33. Szturmowicz M, Tomkowski W, Fijalkowska A, Kupis W, 
Cieslik A, Demkow U, Langfort R, Wiechecka A, Orlowski T, 
Torbicki A. Diagnostic utility of CYFRA 21-1 and CEA 
assays in pericardial fluid for the recognition of neoplastic 
pericarditis. Int J Biol Markers. 2005; 20:43–49.
34. Chen WJ, Chen HW, Yu SL, Huang CH, Wang TD, Chen JJ, 
Chien CT, Chen HY, Yang PC, Lee YT. Gene expression 
profiles in hypoxic preconditioning using cDNA microarray 
analysis: altered expression of an angiogenic factor, 
carcinoembryonic antigen-related cell adhesion molecule 1. 
Shock. 2005; 24:124–131.
35. Kim J, Chang CK, Hayden T, Liu FC, Benjamin J, 
Hamerman JA, Lanier LL, Kang SM. The activating 
immunoreceptor NKG2D and its ligands are involved 
in allograft transplant rejection. J Immunol. 2007; 179: 
6416–6420.
36. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, 
Rammensee HG, Steinle A. Functional expression and release 
of ligands for the activating immunoreceptor NKG2D in 
leukemia. Blood. 2003; 102:1389–1396.
37. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, 
Plymate SR. Prevalent expression of the immunostimulatory 
MHC class I chain-related molecule is counteracted by 
shedding in prostate cancer. J Clin Invest. 2004; 114:560–568.
38. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, 
Salih HR. Soluble MICA in malignant diseases. Int J 
Cancer. 2006; 118:684–687.
39. Fernandez-Morera JL, Rodriguez-Rodero S, Lahoz C, 
Tunon A, Astudillo A, Garcia-Suarez O, Martinez-Borra J, 
Lopez-Vazquez A, Rodrigo L, Gonzalez S, Lopez-Larrea C. 
Soluble MHC class I chain-related protein B serum levels 
correlate with disease activity in relapsing-remitting 
multiple sclerosis. Hum Immunol. 2008; 69:235–240.
40. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, 
Anderson MA, Bamberger AM, Greenson J, Brand RE, 
Ramachandran V, Logsdon CD. CEACAM1, a novel serum 
biomarker for pancreatic cancer. Pancreas. 2007; 34:436–443.
41. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-
Vazquez A, Lopez-Larrea C. NKG2D ligands: key targets of 
the immune response. Trends Immunol. 2008; 29:397–403.
42. Mincheva-Nilsson L, Nagaeva O, Chen T, Stendahl U, 
Antsiferova J, Mogren I, Hernestal J, Baranov V. Placenta-
derived soluble MHC class I chain-related molecules down-
Oncotarget17895www.impactjournals.com/oncotarget
regulate NKG2D receptor on peripheral blood mononuclear 
cells during human pregnancy: a possible novel immune 
escape mechanism for fetal survival. J Immunol. 2006; 
176:3585–3592.
43. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. 
Stimulation of T cell autoreactivity by anomalous 
expression of NKG2D and its MIC ligands in rheumatoid 
arthritis. Proc Natl Acad Sci U S A. 2003; 100:9452–9457.
44. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC 
ligands impair expression of NKG2D and T-cell activation. 
Nature. 2002; 419:734–738.
45. Maisch B. Immunologic regulator and effector functions in 
perimyocarditis, postmyocarditic heart muscle disease and 
dilated cardiomyopathy. Basic Res Cardiol. 1986; 81:217–241.
